- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Oncology Value Coalition: Bringing Precision Medicine Solutions to the Cancer Journey, Part 7
In part 7 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed telehealth and the role of remote care.
While genomic testing has changed the face of cancer care and ensure more informed decision making, designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.
In the latest webinar from The American Journal of Managed Care®'s (AJMC®) Oncology Value Coalition, experts from City of Hope and Highmark highlighted the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.
Joseph Alvarnas, MD, of City of Hope and editor-in-chief of AJMC®'s Evidence-Based Oncology™, moderated a discussion with:
- Afsaneh Barzi, MD, PhD, medical director, GI oncology, AccessHope; director, employer strategy, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope
- Sameera Rahman, MD, senior medical director, Highmark Inc
- Howard (Jack) West, MD, executive medical director, AccessHope; associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope
In segment 7, panelists discuss telehealth and the role of remote care.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
